• English
  • Sign In
  • Contact Us
×
Catalog Products » GenCRISPR™ Cas9 v1.1

GenCRISPR™ Cas9 v1.1

GenCRISPR™ Cas9 V1.1

A 20 μl reaction in 1 × Cas9 Nuclease Reaction Buffer containing linearized plasmid, gRNA, and Cas9 for 1 hour at 37 °C results in a digestion efficiency of linearized plasmid higher than 90%, as determined by agarose gel electrophoresis.

GenCRISPR™ Cas9 V1.1

Human Jurkat cells were cultured for the test. The cells were transfected with GenCRISPR™ Cas9 v1.1 (Z03701)+ sgRNA (synthesized from GenScript [email protected]) for human TCRαβ gene knock out by electroporation. After transfection and cell culture, measure the gene editing efficiency. GenCRISPR™ Cas9 v1.1 shows a much high editing efficiency.

GenCRISPR™ Cas9 V1.1

Human T cells were cultured for the test. The cells were transfected with GenCRISPR™ Cas9 v1.1 (Z03701)+ sgRNA (synthesized from GenScript [email protected]) + dsDNA template (synthesized from GenScript [email protected]) for knock in test at TCRαβ site by electroporation. After transfection and cell culture, measure the editing efficiency.

The GenCRISPR™ Cas9 v1.1 can be formed with the guide RNA into a ribonucleoprotien (RNP) complex. The use of an RNP complex to perform gene editing has been shown to reduce the challenges encountered with other CRISPR gene editing techniques such as viral and plasmid delivery. Challenges include off-target effects, cell viability and transcription/translational challenges.


GenCRISPR™ Cas9 v1.1 is a tag free nuclease produced by expression in an E. coli strain carrying a plasmid encoding the Cas9 gene from Streptococcus pyogenes with a biparticle nucleus localization signal (BPNLS) at both N-terminal and C-terminal. It has been reported that BPNLS is able to improve the gene editing efficiency.

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.

Source Recombinant Cas9 with a BPNLS at both N-terminal and C-terminal expressed by E.coli 
Species Streptococcus pyogenes
Tag Tag-free
Molecular Weight ~160 kDa
Concentration 4 mg/ml
Active temperature This Cas9 is active at 37 °C.
Formulation Supplied as a solution of 25 mM Tris, 300 mM NaCl, 0.1 mM EDTA, 50% glycerol, pH 8.0.
Storage This product remains stable for up to 12 months at -20 °C. Avoid repeated freeze-thaw cycles.

Key Features High knockout efficiencies: Consistent high editing efficiency in in-vitro and in-vivo.
Tag-free: No extra tag amino acid. 
DNA-free: No external DNA added to the system.

gRNA-dependent double-stranded DNA cleavage

Appearance Clear, colorless liquid
Purity ≥ 90% as analyzed by SDS-PAGE
Concentration by A280 4 mg/ml±10% 
Bioactivity (in vitro) ≥ 90%
Residual DNase Non-specific DNase activity
Residual RNase Non-specific RNase activity
Endotoxin Level ≤ 100 EU/mg as analyzed by gel clotting method

  • GenCRISPR™ Cas9 V1.1
  • GenCRISPR™ Cas9 V1.1

    A 20 μl reaction in 1 × Cas9 Nuclease Reaction Buffer containing linearized plasmid, gRNA, and Cas9 for 1 hour at 37 °C results in a digestion efficiency of linearized plasmid higher than 90%, as determined by agarose gel electrophoresis.

  • GenCRISPR™ Cas9 V1.1
  • GenCRISPR™ Cas9 V1.1

    Human Jurkat cells were cultured for the test. The cells were transfected with GenCRISPR™ Cas9 v1.1 (Z03701)+ sgRNA (synthesized from GenScript [email protected]) for human TCRαβ gene knock out by electroporation. After transfection and cell culture, measure the gene editing efficiency. GenCRISPR™ Cas9 v1.1 shows a much high editing efficiency.

  • GenCRISPR™ Cas9 V1.1
  • GenCRISPR™ Cas9 V1.1

    Human T cells were cultured for the test. The cells were transfected with GenCRISPR™ Cas9 v1.1 (Z03701)+ sgRNA (synthesized from GenScript [email protected]) + dsDNA template (synthesized from GenScript [email protected]) for knock in test at TCRαβ site by electroporation. After transfection and cell culture, measure the editing efficiency.


References 1.      Liu, Xinyi, et al. "Improving editing efficiency for the sequences with NGH PAM using xCas9-derived base editors." Molecular Therapy-Nucleic Acids 17 (2019): 626-635. 
2.      Pollard, Victoria W., et al. "A novel receptor-mediated nuclear protein import pathway." Cell 86.6 (1996): 985-994. 
3.      Koblan, Luke W., et al. "Improving cytidine and adenine base editors by expression optimization and ancestral reconstruction." Nature biotechnology 36.9 (2018): 843-846.



Notice there is no results found, you can visit "Citations Database" for other results.




For more documents, please visit "Technical Support".

Cat. No. Z03701
Size Price
100 μg $206.80
500 μg $704.00
1 mg $1189.10